
    <!DOCTYPE html>
    <html>
    <head>
        <title>Biotech Catalyst Radar Report</title>
        <script src="https://cdn.plot.ly/plotly-latest.min.js"></script>
        <style>
            body { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; margin: 0; padding: 20px; background: #f5f5f5; }
            .container { max_width: 1200px; margin: 0 auto; background: white; padding: 20px; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); }
            h1 { color: #333; }
            .metadata { color: #666; font-size: 0.9em; margin-bottom: 20px; }
            .chart-container { margin-bottom: 40px; border: 1px solid #eee; padding: 10px; border-radius: 4px; }
            table { width: 100%; border-collapse: collapse; margin-top: 20px; }
            th, td { padding: 12px; text-align: left; border-bottom: 1px solid #ddd; }
            th { background-color: #f8f9fa; }
        </style>
    </head>
    <body>
        <div class="container">
            <h1>Biotech Catalyst Radar Report</h1>
            <div class="metadata">Generated on: 2025-12-13 02:37:58</div>
            
            <div class="chart-container">
                <div>                        <script type="text/javascript">window.PlotlyConfig = {MathJaxConfig: 'local'};</script>
        <script charset="utf-8" src="https://cdn.plot.ly/plotly-3.3.0.min.js" integrity="sha256-bO3dS6yCpk9aK4gUpNELtCiDeSYvGYnK7jFI58NQnHI=" crossorigin="anonymous"></script>                <div id="93f9bc5d-6919-47ff-8399-e3ab5e2051c2" class="plotly-graph-div" style="height:5320px; width:100%;"></div>            <script type="text/javascript">                window.PLOTLYENV=window.PLOTLYENV || {};                                if (document.getElementById("93f9bc5d-6919-47ff-8399-e3ab5e2051c2")) {                    Plotly.newPlot(                        "93f9bc5d-6919-47ff-8399-e3ab5e2051c2",                        [{"customdata":[["Dendritic Cell Vaccines Against Her2\u002fHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma",null],["Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML","Acute Myeloid Leukemia",null],["Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm",null],["Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","AML, ALL, MDS",null],["Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","Colorectal Cancer",null],["Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer","PMMR, MSS, MSI-L",null],["Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I\u002fII\uff0cMulti-center, Clinical Study.","Neuroblastoma",null],["Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma","Melasma (Facial Melasma)",null],["Feasibility of Semaglutide in Advanced Lung Disease","Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease",null],["A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma",null],["A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2\u002fNeu Positive (HER2+) Breast Cancer (BC)","Breast Cancer, HER2-positive",null],["Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)","Solid Tumor, Adult",null],["Cisplatin+Pembrolizumab+RT in Vulvar Cancer","Vulvar Cancer, Vulvar Squamous Cell Carcinoma",null],["RFA Plus Carrizumab vs Carrizumab Alone for HCC","Tumor Immunity, Immunosuppression, Radiofrequency Ablation",null],["Adriamycin and Ifosfamide Combined With Sintilimab","Soft Tissue Sarcoma",null],["Spinal Cord Neuromodulation for Spinal Cord Injury","Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia",null],["Rapid Improvement of Depression of Fluoxetine Combined With ATP","Depression",null],["A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma",null],["Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer \uff08CASTLE-08\uff09","Advanced Biliary Tract Cancer",null],["Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel\u002fCarboplatin in Fertility Preserving Surgery","Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery",null],["VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma","Myeloma, Newly Diagnosed, High Risk",null],["A Study to Evaluate in Patients With Parkinsonian Type Disorders","Idiopathic Parkinson Disease",null],["Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)","Primary Immune Thrombocytopenia",null],["Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)","Advanced Intrahepatic Cholangiocarcinoma",null],["Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis","Atopic Dermatitis",null],["Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)","Hepatocellular Carcinoma",null],["Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E\u002fK Mutated",null],["Terazosin Effect on Cardiac Changes in Early Parkinson's Disease","REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease",null],["RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)","Long COVID, Long COVID-19, Hypersomnia",null],["Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma",null],["Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM","Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes",null],["Doxycycline to Protect Heart Muscle After Heart Attacks","ST Segment Elevation Myocardial Infarction, Heart Failure",null],["Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8",null],["A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders","Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL",null],["Effect of Probiotic Intervention on Travel-Related Health Conditions During Short-Term Overseas Travel","Healthy Adults",null],["A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules","Progression",null],["Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)","DLBCL",null],["Amantadine Therapy for Cognitive Impairment in Long COVID","Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome",null],["Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma","Esophageal Cancer, Nimotuzumab, Chemoradiotherapy",null],["Effects of Mirtazapine on Appetite in Advanced Cancer Patients","Advanced Cancer, Anorexia, Weight Loss",null],["Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7",null],["Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma","Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma",null],["Use of Socially Assistive Robots for Long Term Care Older Adults With Cognitive Impairment and Apathy","Alzheimer Disease",null],["GD2\u002fCD70 Bi-specific CAR-T Cell Therapy","Cancer Disease",null],["Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","Ocular Graft-versus-host Disease",null],["Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)","PTSD",null],["MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia","Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease",null],["Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study","Tuberous Sclerosis Complex, Epilepsy",null],["Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy","Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm",null],["Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck","Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx",null],["Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC","Hepatocellular Carcinoma Non-resectable, HCC",null],["Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation","Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy",null],["\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS\u002fpMMR Colorectal Cancer\"","MCRC",null],["Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers","Metastatic Malignant Female Reproductive System Neoplasm",null],["Phase II Trial of Sacituzumab Govitecan in Recurrent and\u002for Metastatic Secretory Gland Cancers","Gland, Salivary Gland Cancers",null],["Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1\u002f2\u002f3 (Trk A\u002fB\u002fC), ROS1, or ALK Gene Rearrangements (Fusions)","Breast Cancer, Cholangiocarcinoma, Colorectal Cancer",null],["Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation",null],["Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","Esophagus Cancer",null],["A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma","Metastatic Urothelial Carcinoma",null],["Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma","Mesenchymal Chondrosarcoma",null],["CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory\u002fRelapsed Aggressive Non-Hodgkin's Lymphoma (NHL).","Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma",null],["Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness","Asthma, Wheezing",null],["Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery","Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",null],["A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)","Atrial Fibrillation",null],["Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously","Erectile Dysfunction",null],["A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","Melanoma",null],["SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","Anemia",null],["Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","Breast Cancer, Heart Failure",null],["Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV","Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria",null],["Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma",null],["A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon\u00ae, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation\u002fFlutter After Terminating Its Persistent Form","Atrial Fibrillation, Atrial Flutter",null],["Efficacy of CTM for Tennis ELbow","Tennis Elbow, Lateral Epicondylitis \\(Tennis Elbow\\), Lateral Elbow Tendinopathy",null],["Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension","Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease",null],["FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer","Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic",null],["Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","Multiple Sclerosis",null],["Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation","Inflammatory Disease, Aging Problems, Obese",null],["Vaginal Baclofen Suppositories in Chronic Pelvic Pain","Chronic Pelvic Pain Syndrome",null],["Efficacy of Cerebello-spinal Direct Current Stimulation (csDCS) on Functional Mobility in Chronic Stroke Patients","Stroke Rehabilitation, Gait Disorders, Neurologic, tDCS",null],["Intrathecal Combination of Programmed Death-1 (PD-1)\u002fCytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","Leptomeningeal Metastasis",null],["5HTP Regulation Of Asthma In Children","Mild or Moderate Asthma With Allergic Sensitization",null],["Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia","Fibrous Dysplasia",null],["A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","Malaria, Malaria,Falciparum, Parasitic Disease",null],["CAR- PRISM (PRecision Intervention Smoldering Myeloma)","Multiple Myeloma, Smoldering Multiple Myeloma",null],["Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","Sepsis",null],["Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis","Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7",null],["Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","Classical Hodgkin Lymphoma",null],["Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer",null],["Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma",null],["A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors","Advanced or Metastatic Solid Tumors",null],["The da Vinci Single Port Robotic System for Use in Abdominal and Pelvic Surgical Procedures","Disease or Disorder",null],["Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma","Asthma",null],["Trilaciclib Prevents Myelosuppression With Chemoradiotherapy","Myelosuppression",null],["Study of ODX (OsteoDex) in Multiple Myeloma","Multiple Myeloma",null],["Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System",null],["A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity","Hypothalamic Obesity",null],["Atezolizumab + Cabozantinib in Patients w\u002f Metastatic, Refractory Pancreatic Cancer","Pancreatic Cancer, Metastatic Pancreatic Cancer",null],["Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","Sickle Cell Anemia, Beta Thalassemia",null],["Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed\u002fRefractory Acute Myeloid Leukemia","Relapsed\u002fRefractory Acute Myeloid Leukemia",null],["BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","Triple-Negative Breast Cancer (TNBC), Brain Metastases",null],["CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children","Pharmacokinetics of Celecoxib in Children",null],["Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer","Rectal Cancer",null],["Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery","Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer",null],["Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","Salivary Gland Cancer, HER2 Gene Mutation",null],["A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis","Immune-related Colitis, Colitis",null],["A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","Advanced Solid Tumor",null],["Phase II Study of THDBH120 Injection in Overweight or Obese Subjects","Overweight or Obese",null],["A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure","Chronic Heart Failure",null],["NP137 Clinical and Biological Activities Assessment in Patients With Advanced\u002fMetastatic Solid Tumors Treated by Standard Anti PD-1\u002fPD-L1 Immunotherapies","Advanced Solid Tumors, Metastatic Solid Tumors",null],["A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia",null],["Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma","Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma",null],["Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","Colon Cancer",null],["A Study of AT-02 in Subjects With Systemic Amyloidosis.","Amyloidosis; Systemic",null],["Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy","CMV",null],["Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI","STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI)",null],["STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer",null],["Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms","Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome",null],["Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer","Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy",null],["Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis","MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis",null],["Double-blind Pilot Study on the Effect of Anionic Exposome Enrichment (Biow) on Recovery and Sleep Quality in Postoperative Patients","Inflammatory Response After Surgery, Postoperative Recovery",null],["Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer",null],["Efficacy and Safety of 500mg of Fulvestrant","Breast Cancer",null],["Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r\u002fr B-NHL","Non-hodgkin Lymphoma,B Cell",null],["Pembrolizumab in Treating Patients With Malignant Mesothelioma","Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma",null],["GEN1047 for Solid Tumors - First in Human (FIH) Trial","Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms",null],["A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)","Systemic Lupus Erythematosus",null],["APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","Solid Tumors, Advanced Cancer, Renal Cancer",null],["Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome","Acute Coronary Syndrome",null],["Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease","Chronic Kidney Diseases",null],["Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)","Rift Valley Fever",null],["A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma",null],["Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",null],["Antibiotic Prophylaxis for Neurogenic Bladder Botox","Neurogenic Bladder, Post-operative Urinary Tract Infections",null],["Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant","Allogeneic Stem Cell Transplantation",null],["Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients","Metastatic Renal Cell Carcinoma",null],["DOR\u002fTDF\u002f3TC Switch With M184V\u002fI in People With Controlled HIV (Drive Off-Road)","Hiv",null],["A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer",null],["RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)","Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19",null],["A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis","Moderate to Severe Ulcerative Colitis",null],["Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells","Unresectable Hepatocellular Carcinoma",null],["Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage","Sub-arachnoid Haemorrhage",null],["Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","Norovirus Acute Gastroenteritis",null],["Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",null],["Radical Concurrent Chemoradiotherapy With DDP\u002f5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma","Rectal Squamous Cell Carcinoma",null],["A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer","Esophageal Cancer, Dysphagia, Esophageal, Epigallocatechin Gallate",null],["A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma","Hematologic Malignancies",null],["A Modular Phase 1\u002f2 Study With CT7439 in Participants With Solid Malignancies","Solid Malignancies",null],["Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)","Multiple Myeloma",null],["A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy","Chemotherapy-induced Peripheral Neuropathy",null],["Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","Carcinoma, Non-Small-Cell Lung",null],["Dopaminergic Dysfunction in Late-Life Depression","Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant",null],["Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240\u002fPRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)","Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease",null],["a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib",null],["Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8",null],["Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)","Asthma With Allergic Rhinitis",null],["Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","Triple-negative Breast Cancer, Cadonilimab",null],["Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown",null],["Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer","Breast Cancer Female, Hormone Receptor Positive Tumor",null],["Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma","Locally Advanced Thymoma",null],["Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma",null],["Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.","PNH - Paroxysmal Nocturnal Hemoglobinuria",null],["A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms",null],["A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","Metastatic Colorectal Cancer",null],["A Phase \u2160b\u002f\u2161 Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","Acute Myeloid Leukemia, Adult",null],["Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease","Diabetic Kidney Disease (DKD)",null],["Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI","Posttraumatic Headache, Mild Traumatic Brain Injury",null],["Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects","Bronchial Asthma",null],["Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",null],["ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer","Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma",null],["D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)","Major Depressive Disorder",null],["Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age","Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis",null],["A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","Follicular Lymphoma, Marginal Zone Lymphoma",null],["CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease","Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis",null],["BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r\u002fr B-ALL","Acute Lymphocytic Leukemia",null],["Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia","Dyslipidemias",null],["Reducing Innate Inflammation in New Onset Type 1 Diabetes","Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus",null],["Effect of Belimumab on Antibody Titers in Primary APS Patients","Antiphospholipid Syndrome (APS)",null],["A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","Myelofibrosis",null],["R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia","Waldenstr\u00f6m's Macroglobulinemia",null],["A Phase 1\u002f2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia","Glanzmann Thrombasthenia",null],["Detoxification of the Liver In PSC (Dolphin)","Primary Sclerosing Cholangitis",null],["A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old","Lupus Nephritis",null],["CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm",null],["Cabozantinib Combined With Ipilimumab\u002fNivolumab and TACE in Patients With Hepatocellular Carcinoma","Hepatocellular Carcinoma, HCC",null],["Pharmacogenomics for Better Treatment of Fungal Infections in Cancer","Fungal Infection, Haematological Malignancy, Blood Cancer",null],["Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm",null],["Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","Metastatic Pancreatic Ductal Adenocarcinoma",null],["All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","Glioma, IDH Mutation, Astrocytoma",null],["Tocilizumab and Tofacitinib in the Treatment of Vascular Beh\u00e7et's Syndrome","Aneurysm, Behcet Syndrome, Vascular Type",null],["ZN-c3 + Gemcitabine in Pancreatic Cancer","Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma",null],["Effects of Antiviral Therapies on Epstein-Barr Virus Replication","Multiple Sclerosis",null],["A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","Thrombotic Thrombocytopenic Purpura (TTP)",null]],"hovertemplate":"phase=Phase 2\u003cbr\u003eEstimated Completion=%{x}\u003cbr\u003eTicker=%{y}\u003cbr\u003etitle=%{customdata[0]}\u003cbr\u003econdition=%{customdata[1]}\u003cbr\u003emarket_cap=%{customdata[2]}\u003cextra\u003e\u003c\u002fextra\u003e","legendgroup":"Phase 2","marker":{"color":"#636efa","symbol":"circle"},"mode":"markers","name":"Phase 2","orientation":"v","showlegend":true,"x":["2025-12-15T00:00:00.000000000","2025-12-15T00:00:00.000000000","2025-12-16T00:00:00.000000000","2025-12-20T00:00:00.000000000","2025-12-20T00:00:00.000000000","2025-12-20T00:00:00.000000000","2025-12-26T00:00:00.000000000","2025-12-28T00:00:00.000000000","2025-12-28T00:00:00.000000000","2025-12-28T00:00:00.000000000","2025-12-29T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2026-01-01T00:00:00.000000000","2026-01-01T00:00:00.000000000","2026-01-01T00:00:00.000000000","2026-01-01T00:00:00.000000000","2026-01-01T00:00:00.000000000","2026-01-05T00:00:00.000000000","2026-01-09T00:00:00.000000000","2026-01-10T00:00:00.000000000","2026-01-15T00:00:00.000000000","2026-01-15T00:00:00.000000000","2026-01-15T00:00:00.000000000","2026-01-15T00:00:00.000000000","2026-01-20T00:00:00.000000000","2026-01-21T00:00:00.000000000","2026-01-27T00:00:00.000000000","2026-01-27T00:00:00.000000000","2026-01-29T00:00:00.000000000","2026-01-30T00:00:00.000000000","2026-01-30T00:00:00.000000000","2026-01-30T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-13T00:00:00.000000000","2026-02-24T00:00:00.000000000","2026-02-24T00:00:00.000000000","2026-02-25T00:00:00.000000000","2026-02-28T00:00:00.000000000","2026-02-28T00:00:00.000000000","2026-02-28T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-15T00:00:00.000000000","2026-03-15T00:00:00.000000000","2026-03-20T00:00:00.000000000","2026-03-20T00:00:00.000000000","2026-03-26T00:00:00.000000000","2026-03-29T00:00:00.000000000","2026-03-30T00:00:00.000000000","2026-03-30T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-04-01T00:00:00.000000000","2026-04-01T00:00:00.000000000","2026-04-01T00:00:00.000000000","2026-04-01T00:00:00.000000000","2026-04-03T00:00:00.000000000","2026-04-05T00:00:00.000000000","2026-04-13T00:00:00.000000000","2026-04-14T00:00:00.000000000","2026-04-19T00:00:00.000000000","2026-04-20T00:00:00.000000000","2026-04-22T00:00:00.000000000","2026-04-22T00:00:00.000000000","2026-04-22T00:00:00.000000000","2026-04-26T00:00:00.000000000","2026-04-26T00:00:00.000000000","2026-04-28T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-05-01T00:00:00.000000000","2026-05-01T00:00:00.000000000","2026-05-01T00:00:00.000000000","2026-05-01T00:00:00.000000000","2026-05-06T00:00:00.000000000","2026-05-11T00:00:00.000000000","2026-05-15T00:00:00.000000000","2026-05-15T00:00:00.000000000","2026-05-15T00:00:00.000000000","2026-05-19T00:00:00.000000000","2026-05-26T00:00:00.000000000","2026-05-26T00:00:00.000000000","2026-05-28T00:00:00.000000000","2026-05-29T00:00:00.000000000","2026-05-29T00:00:00.000000000","2026-05-30T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-04T00:00:00.000000000","2026-06-11T00:00:00.000000000"],"xaxis":"x","y":[[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],["VYGR",88],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["PFE",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["CARA",80],[null,0],["AZN",100],[null,0],[null,0],[null,0],["PHAT",91],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["BEAM",82],[null,0],["AZN",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["BMY",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],["MRNA",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["MRK",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["DGXA",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["BMY",100],[null,0],[null,0],[null,0],["BIIB",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0]],"yaxis":"y","type":"scatter"},{"customdata":[["A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India","Rotavirus Infection of Children",null],["A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","Cough, Refractory Chronic Cough",null],["Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Pancreatic Diseases",null],["B\u002fF\u002fTAF to DTG\u002f3TC Switch Study","HIV-1-infection",null],["A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients","Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)",null],["Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors","Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm",null],["The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years","Diffuse Large B-Cell Lymphoma",null],["Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia","Iron Deficiency Anemia of Pregnancy",null],["Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","Non-small Cell Lung Cancer",null],["Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",null],["A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer","Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus",null],["Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","Endometrial Cancer, Atypical Endometrial Hyperplasia",null],["Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","Colorectal Cancer",null],["Maximal Tumor Eradication for Oligometastatic Prostate Cancer","Oligometastatic Prostate Cancer",null],["An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old","Cervical Cancer, Condylomata Acuminata",null],["Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis","Cardiac Amyloidosis",null],["Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)","Ischemic Stroke, Acute",null],["Phase III Study of Toripalimab\uff08JS001\uff09 Combined With Lenvatinib for Advanced HCC","Advanced Hepatocellular Carcinoma (HCC)",null],["The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients","Methanol Poisoning",null],["Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia","Chronic Primary Immune Thrombocytopenia (ITP)",null],["Long-term Safety Study of Chronocort in the Treatment of Participants with Congenital Adrenal Hyperplasia","Congenital Adrenal Hyperplasia",null],["High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","Anemia",null],["A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy","Non-small Cell Lung Cancer (NSCLC)",null],["Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression","Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative",null],["IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia","Focal Hand Dystonia",null],["Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","T-cell Lymphoblastic Lymphoma",null],["A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR\u002fMSI Status","Toripalimab, Radiation",null],["An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","Acute Myeloid Leukemia (AML)",null],["Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab","Cancer",null],["Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204\u002fKEYNOTE-204)","Hodgkin Lymphoma",null],["A Study of HS-20094 in Chinese Adults with Overweight or Obesity","Overweight, Obesity",null],["A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","Hepatocellular Carcinoma",null],["A Study of Daratumumab","Multiple Myeloma",null],["The Study of Efficacy and Safety of Dimephosphon\u00ae in Acute Ischemic Stroke","Stroke, Acute Stroke, Ischemic Stroke",null],["A Multi-center, Randomized, Double-blind, Phase II\u002fIII Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","Recurrent or Metastatic Nasopharyngeal Carcinoma",null],["Natural Versus Programmed Frozen Embryo Transfer (NatPro)","Pregnancy Related, Pre-Eclampsia",null],["A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease","Thyroid Eye Disease",null],["A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","Carcinoma, Renal Cell",null],["Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)","Branch Atheromatous Disease",null],["Regorafenib-pembrolizumab vs. TACE\u002fTARE in Intermediate Stage HCC Beyond Up-to-7","Carcinoma, Hepatocellular",null],["Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","Non-Small Cell Lung Cancer",null],["Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache","Posttraumatic Headache",null],["Clinical and Radiographic Evaluation of Three Biomimetic Materials in Pulp Therapy of Immature Young Permanent Teeth \"A Randomized Controlled Clinical Trial\"","Pulpotomy of Young Permanent Molars",null],["Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","Gastric or Esophagogastric Junction Adenocarcinoma",null],["A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","Warm Autoimmune Hemolytic Anemia (wAIHA)",null],["Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy","Modified Radical Mastectomy, Breast Cancer",null],["A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer","Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)",null],["An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM","Obstructive Hypertrophic Cardiomyopathy",null],["A Clinical Study Evaluating the Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant to Testosterone-Deprivation Therapy","Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC V8",null],["Combination of Hypothermia and Thrombectomy in Acute Stroke","Ischemic Stroke, Large Vessel Occlusion, Endovascular Treatment",null],["Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer",null],["An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)","Hidradenitis Suppurativa",null],["Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia","Paroxysmal Supraventricular Tachycardia",null],["AMX0035 and Progressive Supranuclear Palsy","Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases",null],["An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","Thyroid Eye Disease",null],["24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - \u003c18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","Chronic Spontaneous Urticaria",null],["Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)","Burns Surgery",null],["Liposomal Bupivacaine Use in Alveolar Bone Graft Patients","Cleft Lip and Palate",null],["TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","Non Small Cell Lung Cancer",null],["Evaluation of Long-term Safety and Efficacy of ELX\u002fTEZ\u002fIVA in Cystic Fibrosis (CF) Participants 2 Years and Older","Cystic Fibrosis",null],["Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)","Primary Immunodeficiency Disease",null],["Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","Relapsing Multiple Sclerosis",null],["Neighborhood Park Youth Sports Program Fee Waiver and Intensive Family Outreach","Physical Activity",null],["Ketogenic Diet for New-Onset Absence Epilepsy","Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence",null],["Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes","Stem Cells, Type 1 Diabetes",null],["A Study of Intra-operative Imaging in Women With Ovarian Cancer","Ovarian Cancer, Ovarian Carcinoma",null],["A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","Psoriatic Arthritis",null],["Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","Hepatocellular Carcinoma",null],["Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)","Sickle Cell Disease",null],["Phase 2\u002f3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease","Proteinuric Kidney Disease",null],["Faecal Microbiota Transplantation for Liver Cirrhosis","Liver Cirrhosis",null],["Comparison of Standard vs. Accelerated Corneal Crosslinking","Keratoconus, Ectasia Corneal",null],["A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","Diabetes Mellitus, Type 2",null],["Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","Esophageal Squamous Cell Carcinoma",null],["Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa","Choroideremia, X-Linked Retinitis Pigmentosa",null]],"hovertemplate":"phase=Phase 3\u003cbr\u003eEstimated Completion=%{x}\u003cbr\u003eTicker=%{y}\u003cbr\u003etitle=%{customdata[0]}\u003cbr\u003econdition=%{customdata[1]}\u003cbr\u003emarket_cap=%{customdata[2]}\u003cextra\u003e\u003c\u002fextra\u003e","legendgroup":"Phase 3","marker":{"color":"#EF553B","symbol":"circle"},"mode":"markers","name":"Phase 3","orientation":"v","showlegend":true,"x":["2025-12-15T00:00:00.000000000","2025-12-18T00:00:00.000000000","2025-12-20T00:00:00.000000000","2025-12-22T00:00:00.000000000","2025-12-22T00:00:00.000000000","2025-12-23T00:00:00.000000000","2025-12-25T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-30T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2025-12-31T00:00:00.000000000","2026-01-01T00:00:00.000000000","2026-01-07T00:00:00.000000000","2026-01-12T00:00:00.000000000","2026-01-27T00:00:00.000000000","2026-01-28T00:00:00.000000000","2026-01-30T00:00:00.000000000","2026-01-31T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-01T00:00:00.000000000","2026-02-10T00:00:00.000000000","2026-02-11T00:00:00.000000000","2026-02-22T00:00:00.000000000","2026-02-28T00:00:00.000000000","2026-02-28T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-01T00:00:00.000000000","2026-03-02T00:00:00.000000000","2026-03-03T00:00:00.000000000","2026-03-15T00:00:00.000000000","2026-03-15T00:00:00.000000000","2026-03-15T00:00:00.000000000","2026-03-18T00:00:00.000000000","2026-03-26T00:00:00.000000000","2026-03-27T00:00:00.000000000","2026-03-31T00:00:00.000000000","2026-04-01T00:00:00.000000000","2026-04-01T00:00:00.000000000","2026-04-02T00:00:00.000000000","2026-04-18T00:00:00.000000000","2026-04-24T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-04-30T00:00:00.000000000","2026-05-01T00:00:00.000000000","2026-05-01T00:00:00.000000000","2026-05-03T00:00:00.000000000","2026-05-25T00:00:00.000000000","2026-05-29T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-05-31T00:00:00.000000000","2026-06-01T00:00:00.000000000","2026-06-02T00:00:00.000000000","2026-06-02T00:00:00.000000000","2026-06-04T00:00:00.000000000"],"xaxis":"x","y":[[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],[null,0],[null,0],[null,0],["AZN",100],["MRK",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["AMGN",100],["MRK",100],[null,0],[null,0],["NVS",100],[null,0],[null,0],[null,0],["NVS",100],[null,0],[null,0],["OLMA",81],[null,0],[null,0],[null,0],[null,0],["MIST",100],["ALNY",87],["VKTX",88],["NVS",100],[null,0],[null,0],[null,0],["VRTX",100],[null,0],["NVS",100],[null,0],[null,0],[null,0],[null,0],[null,0],["AZN",100],[null,0],["VRTX",100],[null,0],[null,0],[null,0],["AZN",100],["BIIB",100]],"yaxis":"y","type":"scatter"}],                        {"template":{"data":{"histogram2dcontour":[{"type":"histogram2dcontour","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"choropleth":[{"type":"choropleth","colorbar":{"outlinewidth":0,"ticks":""}}],"histogram2d":[{"type":"histogram2d","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"heatmap":[{"type":"heatmap","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"contourcarpet":[{"type":"contourcarpet","colorbar":{"outlinewidth":0,"ticks":""}}],"contour":[{"type":"contour","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"surface":[{"type":"surface","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"mesh3d":[{"type":"mesh3d","colorbar":{"outlinewidth":0,"ticks":""}}],"scatter":[{"fillpattern":{"fillmode":"overlay","size":10,"solidity":0.2},"type":"scatter"}],"parcoords":[{"type":"parcoords","line":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterpolargl":[{"type":"scatterpolargl","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"bar":[{"error_x":{"color":"#2a3f5f"},"error_y":{"color":"#2a3f5f"},"marker":{"line":{"color":"#E5ECF6","width":0.5},"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"bar"}],"scattergeo":[{"type":"scattergeo","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterpolar":[{"type":"scatterpolar","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"histogram":[{"marker":{"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"histogram"}],"scattergl":[{"type":"scattergl","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatter3d":[{"type":"scatter3d","line":{"colorbar":{"outlinewidth":0,"ticks":""}},"marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattermap":[{"type":"scattermap","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattermapbox":[{"type":"scattermapbox","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterternary":[{"type":"scatterternary","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattercarpet":[{"type":"scattercarpet","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"carpet":[{"aaxis":{"endlinecolor":"#2a3f5f","gridcolor":"white","linecolor":"white","minorgridcolor":"white","startlinecolor":"#2a3f5f"},"baxis":{"endlinecolor":"#2a3f5f","gridcolor":"white","linecolor":"white","minorgridcolor":"white","startlinecolor":"#2a3f5f"},"type":"carpet"}],"table":[{"cells":{"fill":{"color":"#EBF0F8"},"line":{"color":"white"}},"header":{"fill":{"color":"#C8D4E3"},"line":{"color":"white"}},"type":"table"}],"barpolar":[{"marker":{"line":{"color":"#E5ECF6","width":0.5},"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"barpolar"}],"pie":[{"automargin":true,"type":"pie"}]},"layout":{"autotypenumbers":"strict","colorway":["#636efa","#EF553B","#00cc96","#ab63fa","#FFA15A","#19d3f3","#FF6692","#B6E880","#FF97FF","#FECB52"],"font":{"color":"#2a3f5f"},"hovermode":"closest","hoverlabel":{"align":"left"},"paper_bgcolor":"white","plot_bgcolor":"#E5ECF6","polar":{"bgcolor":"#E5ECF6","angularaxis":{"gridcolor":"white","linecolor":"white","ticks":""},"radialaxis":{"gridcolor":"white","linecolor":"white","ticks":""}},"ternary":{"bgcolor":"#E5ECF6","aaxis":{"gridcolor":"white","linecolor":"white","ticks":""},"baxis":{"gridcolor":"white","linecolor":"white","ticks":""},"caxis":{"gridcolor":"white","linecolor":"white","ticks":""}},"coloraxis":{"colorbar":{"outlinewidth":0,"ticks":""}},"colorscale":{"sequential":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]],"sequentialminus":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]],"diverging":[[0,"#8e0152"],[0.1,"#c51b7d"],[0.2,"#de77ae"],[0.3,"#f1b6da"],[0.4,"#fde0ef"],[0.5,"#f7f7f7"],[0.6,"#e6f5d0"],[0.7,"#b8e186"],[0.8,"#7fbc41"],[0.9,"#4d9221"],[1,"#276419"]]},"xaxis":{"gridcolor":"white","linecolor":"white","ticks":"","title":{"standoff":15},"zerolinecolor":"white","automargin":true,"zerolinewidth":2},"yaxis":{"gridcolor":"white","linecolor":"white","ticks":"","title":{"standoff":15},"zerolinecolor":"white","automargin":true,"zerolinewidth":2},"scene":{"xaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2},"yaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2},"zaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2}},"shapedefaults":{"line":{"color":"#2a3f5f"}},"annotationdefaults":{"arrowcolor":"#2a3f5f","arrowhead":0,"arrowwidth":1},"geo":{"bgcolor":"white","landcolor":"#E5ECF6","subunitcolor":"white","showland":true,"showlakes":true,"lakecolor":"white"},"title":{"x":0.05},"mapbox":{"style":"light"}}},"xaxis":{"anchor":"y","domain":[0.0,1.0],"title":{"text":"Estimated Completion"}},"yaxis":{"anchor":"x","domain":[0.0,1.0],"title":{"text":"Ticker"}},"legend":{"title":{"text":"phase"},"tracegroupgap":0},"title":{"text":"Upcoming Biotech Catalysts (Timeline)"},"height":5320},                        {"responsive": true}                    )                };            </script>        </div>
            </div>
            
            <div class="chart-container">
                <div>                            <div id="ef18bc1d-52aa-4048-a53e-51d4ff313c92" class="plotly-graph-div" style="height:100%; width:100%;"></div>            <script type="text/javascript">                window.PLOTLYENV=window.PLOTLYENV || {};                                if (document.getElementById("ef18bc1d-52aa-4048-a53e-51d4ff313c92")) {                    Plotly.newPlot(                        "ef18bc1d-52aa-4048-a53e-51d4ff313c92",                        [{"customdata":[["Dendritic Cell Vaccines Against Her2\u002fHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma",0.0],["Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML","Acute Myeloid Leukemia",0.0],["Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm",0.0],["Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","AML, ALL, MDS",0.0],["Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","Colorectal Cancer",0.0],["Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer","PMMR, MSS, MSI-L",0.0],["Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I\u002fII\uff0cMulti-center, Clinical Study.","Neuroblastoma",0.0],["Feasibility of Semaglutide in Advanced Lung Disease","Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease",0.0],["A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma",0.0],["Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma","Melasma (Facial Melasma)",0.0],["A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2\u002fNeu Positive (HER2+) Breast Cancer (BC)","Breast Cancer, HER2-positive",0.0],["Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)","Primary Immune Thrombocytopenia",0.0],["Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)","Advanced Intrahepatic Cholangiocarcinoma",0.0],["Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)","Hepatocellular Carcinoma",0.0],["Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis","Atopic Dermatitis",0.0],["Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E\u002fK Mutated",0.0],["Terazosin Effect on Cardiac Changes in Early Parkinson's Disease","REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease",0.0],["VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma","Myeloma, Newly Diagnosed, High Risk",0.0],["A Study to Evaluate in Patients With Parkinsonian Type Disorders","Idiopathic Parkinson Disease",0.0],["Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer \uff08CASTLE-08\uff09","Advanced Biliary Tract Cancer",0.0],["Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)","Solid Tumor, Adult",0.0],["A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma",0.0],["Rapid Improvement of Depression of Fluoxetine Combined With ATP","Depression",0.0],["Spinal Cord Neuromodulation for Spinal Cord Injury","Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia",0.0],["Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel\u002fCarboplatin in Fertility Preserving Surgery","Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery",0.0],["Adriamycin and Ifosfamide Combined With Sintilimab","Soft Tissue Sarcoma",0.0],["RFA Plus Carrizumab vs Carrizumab Alone for HCC","Tumor Immunity, Immunosuppression, Radiofrequency Ablation",0.0],["Cisplatin+Pembrolizumab+RT in Vulvar Cancer","Vulvar Cancer, Vulvar Squamous Cell Carcinoma",0.0],["Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously","Erectile Dysfunction",0.0],["Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers","Metastatic Malignant Female Reproductive System Neoplasm",0.0],["Phase II Trial of Sacituzumab Govitecan in Recurrent and\u002for Metastatic Secretory Gland Cancers","Gland, Salivary Gland Cancers",0.0],["Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1\u002f2\u002f3 (Trk A\u002fB\u002fC), ROS1, or ALK Gene Rearrangements (Fusions)","Breast Cancer, Cholangiocarcinoma, Colorectal Cancer",0.0],["Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation",0.0],["Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","Esophagus Cancer",0.0],["A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma","Metastatic Urothelial Carcinoma",0.0],["Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma","Mesenchymal Chondrosarcoma",0.0],["CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory\u002fRelapsed Aggressive Non-Hodgkin's Lymphoma (NHL).","Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma",0.0],["Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness","Asthma, Wheezing",0.0],["Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery","Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",0.0],["A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)","Atrial Fibrillation",0.0],["Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","Breast Cancer, Heart Failure",0.0],["Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension","Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease",0.0],["Efficacy of CTM for Tennis ELbow","Tennis Elbow, Lateral Epicondylitis \\(Tennis Elbow\\), Lateral Elbow Tendinopathy",0.0],["A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon\u00ae, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation\u002fFlutter After Terminating Its Persistent Form","Atrial Fibrillation, Atrial Flutter",0.0],["Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma",0.0],["FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer","Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic",0.0],["Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC","Hepatocellular Carcinoma Non-resectable, HCC",0.0],["SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","Anemia",0.0],["Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV","Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria",0.0],["A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","Melanoma",0.0],["Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation","Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy",0.0],["\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS\u002fpMMR Colorectal Cancer\"","MCRC",0.0],["Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck","Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx",0.0],["Effect of Probiotic Intervention on Travel-Related Health Conditions During Short-Term Overseas Travel","Healthy Adults",0.0],["Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8",0.0],["Doxycycline to Protect Heart Muscle After Heart Attacks","ST Segment Elevation Myocardial Infarction, Heart Failure",0.0],["Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM","Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes",0.0],["Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma",0.0],["RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)","Long COVID, Long COVID-19, Hypersomnia",0.0],["A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders","Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL",0.0],["A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules","Progression",0.0],["Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy","Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm",0.0],["Amantadine Therapy for Cognitive Impairment in Long COVID","Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome",0.0],["Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma","Esophageal Cancer, Nimotuzumab, Chemoradiotherapy",0.0],["Effects of Mirtazapine on Appetite in Advanced Cancer Patients","Advanced Cancer, Anorexia, Weight Loss",0.0],["Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7",0.0],["Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)","DLBCL",0.0],["Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma","Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma",0.0],["Use of Socially Assistive Robots for Long Term Care Older Adults With Cognitive Impairment and Apathy","Alzheimer Disease",0.0],["GD2\u002fCD70 Bi-specific CAR-T Cell Therapy","Cancer Disease",0.0],["Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","Ocular Graft-versus-host Disease",0.0],["Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)","PTSD",0.0],["MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia","Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease",0.0],["Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study","Tuberous Sclerosis Complex, Epilepsy",0.0],["Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","Multiple Sclerosis",0.0],["Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation","Inflammatory Disease, Aging Problems, Obese",0.0],["Vaginal Baclofen Suppositories in Chronic Pelvic Pain","Chronic Pelvic Pain Syndrome",0.0],["Efficacy of Cerebello-spinal Direct Current Stimulation (csDCS) on Functional Mobility in Chronic Stroke Patients","Stroke Rehabilitation, Gait Disorders, Neurologic, tDCS",0.0],["Intrathecal Combination of Programmed Death-1 (PD-1)\u002fCytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","Leptomeningeal Metastasis",0.0],["5HTP Regulation Of Asthma In Children","Mild or Moderate Asthma With Allergic Sensitization",0.0],["Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia","Fibrous Dysplasia",0.0],["A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","Malaria, Malaria,Falciparum, Parasitic Disease",0.0],["CAR- PRISM (PRecision Intervention Smoldering Myeloma)","Multiple Myeloma, Smoldering Multiple Myeloma",0.0],["Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","Sepsis",0.0],["Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis","Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7",0.0],["Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","Classical Hodgkin Lymphoma",0.0],["Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer",0.0],["Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma",0.0],["The da Vinci Single Port Robotic System for Use in Abdominal and Pelvic Surgical Procedures","Disease or Disorder",0.0],["A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors","Advanced or Metastatic Solid Tumors",0.0],["Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma","Asthma",0.0],["Trilaciclib Prevents Myelosuppression With Chemoradiotherapy","Myelosuppression",0.0],["Study of ODX (OsteoDex) in Multiple Myeloma","Multiple Myeloma",0.0],["Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System",0.0],["BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","Triple-Negative Breast Cancer (TNBC), Brain Metastases",0.0],["CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children","Pharmacokinetics of Celecoxib in Children",0.0],["Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","Sickle Cell Anemia, Beta Thalassemia",0.0],["Atezolizumab + Cabozantinib in Patients w\u002f Metastatic, Refractory Pancreatic Cancer","Pancreatic Cancer, Metastatic Pancreatic Cancer",0.0],["Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed\u002fRefractory Acute Myeloid Leukemia","Relapsed\u002fRefractory Acute Myeloid Leukemia",0.0],["A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity","Hypothalamic Obesity",0.0],["Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer","Rectal Cancer",0.0],["Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery","Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer",0.0],["Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","Salivary Gland Cancer, HER2 Gene Mutation",0.0],["A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis","Immune-related Colitis, Colitis",0.0],["A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","Advanced Solid Tumor",0.0],["Phase II Study of THDBH120 Injection in Overweight or Obese Subjects","Overweight or Obese",0.0],["A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure","Chronic Heart Failure",0.0],["NP137 Clinical and Biological Activities Assessment in Patients With Advanced\u002fMetastatic Solid Tumors Treated by Standard Anti PD-1\u002fPD-L1 Immunotherapies","Advanced Solid Tumors, Metastatic Solid Tumors",0.0],["A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia",0.0],["Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma","Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma",0.0],["Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","Colon Cancer",0.0],["A Study of AT-02 in Subjects With Systemic Amyloidosis.","Amyloidosis; Systemic",0.0],["Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy","CMV",0.0],["Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI","STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI)",0.0],["STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer",0.0],["Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms","Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome",0.0],["Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer","Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy",0.0],["Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis","MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis",0.0],["Double-blind Pilot Study on the Effect of Anionic Exposome Enrichment (Biow) on Recovery and Sleep Quality in Postoperative Patients","Inflammatory Response After Surgery, Postoperative Recovery",0.0],["Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer",0.0],["Efficacy and Safety of 500mg of Fulvestrant","Breast Cancer",0.0],["Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r\u002fr B-NHL","Non-hodgkin Lymphoma,B Cell",0.0],["Pembrolizumab in Treating Patients With Malignant Mesothelioma","Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma",0.0],["GEN1047 for Solid Tumors - First in Human (FIH) Trial","Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms",0.0],["A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)","Systemic Lupus Erythematosus",0.0],["APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","Solid Tumors, Advanced Cancer, Renal Cancer",0.0],["Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome","Acute Coronary Syndrome",0.0],["Antibiotic Prophylaxis for Neurogenic Bladder Botox","Neurogenic Bladder, Post-operative Urinary Tract Infections",0.0],["Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",0.0],["A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma",0.0],["Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant","Allogeneic Stem Cell Transplantation",0.0],["Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)","Rift Valley Fever",0.0],["Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease","Chronic Kidney Diseases",0.0],["Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients","Metastatic Renal Cell Carcinoma",0.0],["DOR\u002fTDF\u002f3TC Switch With M184V\u002fI in People With Controlled HIV (Drive Off-Road)","Hiv",0.0],["A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer",0.0],["RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)","Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19",0.0],["A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis","Moderate to Severe Ulcerative Colitis",0.0],["Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells","Unresectable Hepatocellular Carcinoma",0.0],["Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage","Sub-arachnoid Haemorrhage",0.0],["Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","Norovirus Acute Gastroenteritis",0.0],["Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study","Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",0.0],["Radical Concurrent Chemoradiotherapy With DDP\u002f5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma","Rectal Squamous Cell Carcinoma",0.0],["A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer","Esophageal Cancer, Dysphagia, Esophageal, Epigallocatechin Gallate",0.0],["A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma","Hematologic Malignancies",0.0],["A Modular Phase 1\u002f2 Study With CT7439 in Participants With Solid Malignancies","Solid Malignancies",0.0],["Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)","Multiple Myeloma",0.0],["A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy","Chemotherapy-induced Peripheral Neuropathy",0.0],["Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","Carcinoma, Non-Small-Cell Lung",0.0],["Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)","Asthma With Allergic Rhinitis",0.0],["Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8",0.0],["Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","Triple-negative Breast Cancer, Cadonilimab",0.0],["Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240\u002fPRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)","Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease",0.0],["a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib",0.0],["Dopaminergic Dysfunction in Late-Life Depression","Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant",0.0],["Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma","Locally Advanced Thymoma",0.0],["Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma",0.0],["Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown",0.0],["Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer","Breast Cancer Female, Hormone Receptor Positive Tumor",0.0],["Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.","PNH - Paroxysmal Nocturnal Hemoglobinuria",0.0],["A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms",0.0],["A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","Metastatic Colorectal Cancer",0.0],["A Phase \u2160b\u002f\u2161 Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","Acute Myeloid Leukemia, Adult",0.0],["Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease","Diabetic Kidney Disease (DKD)",0.0],["Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI","Posttraumatic Headache, Mild Traumatic Brain Injury",0.0],["Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",0.0],["Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects","Bronchial Asthma",0.0],["ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer","Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma",0.0],["D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)","Major Depressive Disorder",0.0],["Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age","Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis",0.0],["A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","Follicular Lymphoma, Marginal Zone Lymphoma",0.0],["A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","Myelofibrosis",0.0],["Effect of Belimumab on Antibody Titers in Primary APS Patients","Antiphospholipid Syndrome (APS)",0.0],["Reducing Innate Inflammation in New Onset Type 1 Diabetes","Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus",0.0],["R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia","Waldenstr\u00f6m's Macroglobulinemia",0.0],["Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia","Dyslipidemias",0.0],["BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r\u002fr B-ALL","Acute Lymphocytic Leukemia",0.0],["CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease","Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis",0.0],["Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm",0.0],["Tocilizumab and Tofacitinib in the Treatment of Vascular Beh\u00e7et's Syndrome","Aneurysm, Behcet Syndrome, Vascular Type",0.0],["All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","Glioma, IDH Mutation, Astrocytoma",0.0],["Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","Metastatic Pancreatic Ductal Adenocarcinoma",0.0],["ZN-c3 + Gemcitabine in Pancreatic Cancer","Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma",0.0],["Pharmacogenomics for Better Treatment of Fungal Infections in Cancer","Fungal Infection, Haematological Malignancy, Blood Cancer",0.0],["A Phase 1\u002f2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia","Glanzmann Thrombasthenia",0.0],["Cabozantinib Combined With Ipilimumab\u002fNivolumab and TACE in Patients With Hepatocellular Carcinoma","Hepatocellular Carcinoma, HCC",0.0],["CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm",0.0],["A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old","Lupus Nephritis",0.0],["Detoxification of the Liver In PSC (Dolphin)","Primary Sclerosing Cholangitis",0.0],["Effects of Antiviral Therapies on Epstein-Barr Virus Replication","Multiple Sclerosis",0.0],["A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","Thrombotic Thrombocytopenic Purpura (TTP)",0.0]],"hovertemplate":"\u003cb\u003e%{hovertext}\u003c\u002fb\u003e\u003cbr\u003e\u003cbr\u003ephase=Phase 2\u003cbr\u003eDays to Catalyst=%{x}\u003cbr\u003eMarket Cap ($)=%{y}\u003cbr\u003esize_metric=%{marker.size}\u003cbr\u003etitle=%{customdata[0]}\u003cbr\u003econdition=%{customdata[1]}\u003cbr\u003epct_change_30d=%{customdata[2]}\u003cextra\u003e\u003c\u002fextra\u003e","hovertext":[[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],["VYGR",88],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["PFE",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["CARA",80],["AZN",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["PHAT",91],[null,0],[null,0],[null,0],[null,0],["BEAM",82],[null,0],["AZN",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["BMY",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],["MRNA",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["MRK",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["DGXA",100],[null,0],["BMY",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["BIIB",100],[null,0],[null,0],[null,0]],"legendgroup":"Phase 2","marker":{"color":"#636efa","size":{"dtype":"f8","bdata":"AAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPw=="},"sizemode":"area","sizeref":0.0025,"symbol":"circle"},"mode":"markers","name":"Phase 2","orientation":"v","showlegend":true,"x":{"dtype":"i2","bdata":"AQABAAIABgAGAAYADAAOAA4ADgAPABAAEAAQABAAEAAQABAAEAAQABAAEAAQABAAEAAQABAAEAARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABEAEQARABIAEgASABIAEgAWABoAGwAgACAAIAAgACUAJgAsACwALgAvAC8ALwAwADAAMAAwADAAMAAxADEAMQAxADEAPQBIAEgASQBMAEwATABNAE0ATQBNAE0ATQBNAFsAWwBgAGAAZgBpAGoAagBrAGsAawBrAGsAawBsAGwAbABsAG4AcAB4AHkAfgB\u002fAIEAgQCBAIUAhQCHAIkAiQCJAIkAiQCJAIoAigCKAIoAjwCUAJgAmACYAJwAowCjAKUApgCmAKcAqACoAKgAqACoAKgAqACpAKkAqQCpAKkAqQCpAKkAqQCpAKkArACzAA=="},"xaxis":"x","y":{"dtype":"f8","bdata":"AAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fw=="},"yaxis":"y","type":"scatter"},{"customdata":[["A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India","Rotavirus Infection of Children",0.0],["A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","Cough, Refractory Chronic Cough",0.0],["Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Pancreatic Diseases",0.0],["B\u002fF\u002fTAF to DTG\u002f3TC Switch Study","HIV-1-infection",0.0],["A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients","Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)",0.0],["Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors","Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm",0.0],["The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years","Diffuse Large B-Cell Lymphoma",0.0],["A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer","Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus",0.0],["Maximal Tumor Eradication for Oligometastatic Prostate Cancer","Oligometastatic Prostate Cancer",0.0],["Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","Endometrial Cancer, Atypical Endometrial Hyperplasia",0.0],["Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","Colorectal Cancer",0.0],["Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",0.0],["Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","Non-small Cell Lung Cancer",0.0],["Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia","Iron Deficiency Anemia of Pregnancy",0.0],["High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","Anemia",0.0],["A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy","Non-small Cell Lung Cancer (NSCLC)",0.0],["Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression","Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative",0.0],["A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR\u002fMSI Status","Toripalimab, Radiation",0.0],["Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","T-cell Lymphoblastic Lymphoma",0.0],["IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia","Focal Hand Dystonia",0.0],["Long-term Safety Study of Chronocort in the Treatment of Participants with Congenital Adrenal Hyperplasia","Congenital Adrenal Hyperplasia",0.0],["Phase III Study of Toripalimab\uff08JS001\uff09 Combined With Lenvatinib for Advanced HCC","Advanced Hepatocellular Carcinoma (HCC)",0.0],["The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients","Methanol Poisoning",0.0],["Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)","Ischemic Stroke, Acute",0.0],["Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis","Cardiac Amyloidosis",0.0],["An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old","Cervical Cancer, Condylomata Acuminata",0.0],["Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia","Chronic Primary Immune Thrombocytopenia (ITP)",0.0],["An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","Acute Myeloid Leukemia (AML)",0.0],["Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab","Cancer",0.0],["Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204\u002fKEYNOTE-204)","Hodgkin Lymphoma",0.0],["A Study of HS-20094 in Chinese Adults with Overweight or Obesity","Overweight, Obesity",0.0],["A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","Hepatocellular Carcinoma",0.0],["A Study of Daratumumab","Multiple Myeloma",0.0],["The Study of Efficacy and Safety of Dimephosphon\u00ae in Acute Ischemic Stroke","Stroke, Acute Stroke, Ischemic Stroke",0.0],["A Multi-center, Randomized, Double-blind, Phase II\u002fIII Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","Recurrent or Metastatic Nasopharyngeal Carcinoma",0.0],["Natural Versus Programmed Frozen Embryo Transfer (NatPro)","Pregnancy Related, Pre-Eclampsia",0.0],["A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease","Thyroid Eye Disease",0.0],["A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","Carcinoma, Renal Cell",0.0],["Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)","Branch Atheromatous Disease",0.0],["Regorafenib-pembrolizumab vs. TACE\u002fTARE in Intermediate Stage HCC Beyond Up-to-7","Carcinoma, Hepatocellular",0.0],["Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","Non-Small Cell Lung Cancer",0.0],["Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache","Posttraumatic Headache",0.0],["Clinical and Radiographic Evaluation of Three Biomimetic Materials in Pulp Therapy of Immature Young Permanent Teeth \"A Randomized Controlled Clinical Trial\"","Pulpotomy of Young Permanent Molars",0.0],["Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","Gastric or Esophagogastric Junction Adenocarcinoma",0.0],["A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","Warm Autoimmune Hemolytic Anemia (wAIHA)",0.0],["Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy","Modified Radical Mastectomy, Breast Cancer",0.0],["A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer","Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)",0.0],["An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM","Obstructive Hypertrophic Cardiomyopathy",0.0],["A Clinical Study Evaluating the Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant to Testosterone-Deprivation Therapy","Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC V8",0.0],["Combination of Hypothermia and Thrombectomy in Acute Stroke","Ischemic Stroke, Large Vessel Occlusion, Endovascular Treatment",0.0],["Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer",0.0],["An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)","Hidradenitis Suppurativa",0.0],["Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia","Paroxysmal Supraventricular Tachycardia",0.0],["AMX0035 and Progressive Supranuclear Palsy","Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases",0.0],["An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","Thyroid Eye Disease",0.0],["24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - \u003c18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","Chronic Spontaneous Urticaria",0.0],["Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)","Burns Surgery",0.0],["Liposomal Bupivacaine Use in Alveolar Bone Graft Patients","Cleft Lip and Palate",0.0],["Neighborhood Park Youth Sports Program Fee Waiver and Intensive Family Outreach","Physical Activity",0.0],["Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","Relapsing Multiple Sclerosis",0.0],["Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)","Primary Immunodeficiency Disease",0.0],["Evaluation of Long-term Safety and Efficacy of ELX\u002fTEZ\u002fIVA in Cystic Fibrosis (CF) Participants 2 Years and Older","Cystic Fibrosis",0.0],["TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","Non Small Cell Lung Cancer",0.0],["Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes","Stem Cells, Type 1 Diabetes",0.0],["Ketogenic Diet for New-Onset Absence Epilepsy","Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence",0.0],["A Study of Intra-operative Imaging in Women With Ovarian Cancer","Ovarian Cancer, Ovarian Carcinoma",0.0],["A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","Psoriatic Arthritis",0.0],["Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","Hepatocellular Carcinoma",0.0],["Faecal Microbiota Transplantation for Liver Cirrhosis","Liver Cirrhosis",0.0],["Phase 2\u002f3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease","Proteinuric Kidney Disease",0.0],["Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)","Sickle Cell Disease",0.0],["Comparison of Standard vs. Accelerated Corneal Crosslinking","Keratoconus, Ectasia Corneal",0.0],["A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","Diabetes Mellitus, Type 2",0.0],["Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","Esophageal Squamous Cell Carcinoma",0.0],["Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa","Choroideremia, X-Linked Retinitis Pigmentosa",0.0]],"hovertemplate":"\u003cb\u003e%{hovertext}\u003c\u002fb\u003e\u003cbr\u003e\u003cbr\u003ephase=Phase 3\u003cbr\u003eDays to Catalyst=%{x}\u003cbr\u003eMarket Cap ($)=%{y}\u003cbr\u003esize_metric=%{marker.size}\u003cbr\u003etitle=%{customdata[0]}\u003cbr\u003econdition=%{customdata[1]}\u003cbr\u003epct_change_30d=%{customdata[2]}\u003cextra\u003e\u003c\u002fextra\u003e","hovertext":[[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["RHHBY",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["AZN",100],["MRK",100],[null,0],[null,0],[null,0],[null,0],[null,0],[null,0],["AMGN",100],["MRK",100],[null,0],[null,0],["NVS",100],[null,0],[null,0],[null,0],["NVS",100],[null,0],[null,0],["OLMA",81],[null,0],[null,0],[null,0],[null,0],["MIST",100],["ALNY",87],["VKTX",88],["NVS",100],[null,0],[null,0],[null,0],["NVS",100],[null,0],["VRTX",100],[null,0],[null,0],[null,0],[null,0],[null,0],["AZN",100],[null,0],["VRTX",100],[null,0],[null,0],[null,0],["AZN",100],["BIIB",100]],"legendgroup":"Phase 3","marker":{"color":"#EF553B","size":{"dtype":"f8","bdata":"AAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002fAAAAAAAA8D8AAAAAAADwPwAAAAAAAPA\u002f"},"sizemode":"area","sizeref":0.0025,"symbol":"circle"},"mode":"markers","name":"Phase 3","orientation":"v","showlegend":true,"x":{"dtype":"i2","bdata":"AQAEAAYACAAIAAkACwAQABAAEAAQABAAEAAQABEAEQARABEAEQARABEAEQARABEAEQARABEAEgAYAB0ALAAtAC8AMAAxADEAOgA7AEYATABMAE0ATQBNAE4ATwBbAFsAWwBeAGYAZwBrAGwAbABtAH0AgwCJAIkAiQCJAIkAigCKAIwAogCmAKgAqACoAKkAqgCqAKwA"},"xaxis":"x","y":{"dtype":"f8","bdata":"AAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002fAAAAAAAA+H8AAAAAAAD4fwAAAAAAAPh\u002f"},"yaxis":"y","type":"scatter"}],                        {"template":{"data":{"histogram2dcontour":[{"type":"histogram2dcontour","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"choropleth":[{"type":"choropleth","colorbar":{"outlinewidth":0,"ticks":""}}],"histogram2d":[{"type":"histogram2d","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"heatmap":[{"type":"heatmap","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"contourcarpet":[{"type":"contourcarpet","colorbar":{"outlinewidth":0,"ticks":""}}],"contour":[{"type":"contour","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"surface":[{"type":"surface","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"mesh3d":[{"type":"mesh3d","colorbar":{"outlinewidth":0,"ticks":""}}],"scatter":[{"fillpattern":{"fillmode":"overlay","size":10,"solidity":0.2},"type":"scatter"}],"parcoords":[{"type":"parcoords","line":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterpolargl":[{"type":"scatterpolargl","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"bar":[{"error_x":{"color":"#2a3f5f"},"error_y":{"color":"#2a3f5f"},"marker":{"line":{"color":"#E5ECF6","width":0.5},"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"bar"}],"scattergeo":[{"type":"scattergeo","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterpolar":[{"type":"scatterpolar","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"histogram":[{"marker":{"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"histogram"}],"scattergl":[{"type":"scattergl","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatter3d":[{"type":"scatter3d","line":{"colorbar":{"outlinewidth":0,"ticks":""}},"marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattermap":[{"type":"scattermap","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattermapbox":[{"type":"scattermapbox","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterternary":[{"type":"scatterternary","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattercarpet":[{"type":"scattercarpet","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"carpet":[{"aaxis":{"endlinecolor":"#2a3f5f","gridcolor":"white","linecolor":"white","minorgridcolor":"white","startlinecolor":"#2a3f5f"},"baxis":{"endlinecolor":"#2a3f5f","gridcolor":"white","linecolor":"white","minorgridcolor":"white","startlinecolor":"#2a3f5f"},"type":"carpet"}],"table":[{"cells":{"fill":{"color":"#EBF0F8"},"line":{"color":"white"}},"header":{"fill":{"color":"#C8D4E3"},"line":{"color":"white"}},"type":"table"}],"barpolar":[{"marker":{"line":{"color":"#E5ECF6","width":0.5},"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"barpolar"}],"pie":[{"automargin":true,"type":"pie"}]},"layout":{"autotypenumbers":"strict","colorway":["#636efa","#EF553B","#00cc96","#ab63fa","#FFA15A","#19d3f3","#FF6692","#B6E880","#FF97FF","#FECB52"],"font":{"color":"#2a3f5f"},"hovermode":"closest","hoverlabel":{"align":"left"},"paper_bgcolor":"white","plot_bgcolor":"#E5ECF6","polar":{"bgcolor":"#E5ECF6","angularaxis":{"gridcolor":"white","linecolor":"white","ticks":""},"radialaxis":{"gridcolor":"white","linecolor":"white","ticks":""}},"ternary":{"bgcolor":"#E5ECF6","aaxis":{"gridcolor":"white","linecolor":"white","ticks":""},"baxis":{"gridcolor":"white","linecolor":"white","ticks":""},"caxis":{"gridcolor":"white","linecolor":"white","ticks":""}},"coloraxis":{"colorbar":{"outlinewidth":0,"ticks":""}},"colorscale":{"sequential":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]],"sequentialminus":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]],"diverging":[[0,"#8e0152"],[0.1,"#c51b7d"],[0.2,"#de77ae"],[0.3,"#f1b6da"],[0.4,"#fde0ef"],[0.5,"#f7f7f7"],[0.6,"#e6f5d0"],[0.7,"#b8e186"],[0.8,"#7fbc41"],[0.9,"#4d9221"],[1,"#276419"]]},"xaxis":{"gridcolor":"white","linecolor":"white","ticks":"","title":{"standoff":15},"zerolinecolor":"white","automargin":true,"zerolinewidth":2},"yaxis":{"gridcolor":"white","linecolor":"white","ticks":"","title":{"standoff":15},"zerolinecolor":"white","automargin":true,"zerolinewidth":2},"scene":{"xaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2},"yaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2},"zaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2}},"shapedefaults":{"line":{"color":"#2a3f5f"}},"annotationdefaults":{"arrowcolor":"#2a3f5f","arrowhead":0,"arrowwidth":1},"geo":{"bgcolor":"white","landcolor":"#E5ECF6","subunitcolor":"white","showland":true,"showlakes":true,"lakecolor":"white"},"title":{"x":0.05},"mapbox":{"style":"light"}}},"xaxis":{"anchor":"y","domain":[0.0,1.0],"title":{"text":"Days to Catalyst"}},"yaxis":{"anchor":"x","domain":[0.0,1.0],"title":{"text":"Market Cap ($)"}},"legend":{"title":{"text":"phase"},"tracegroupgap":0,"itemsizing":"constant"},"title":{"text":"Market Cap vs. Time to Catalyst"}},                        {"responsive": true}                    )                };            </script>        </div>
            </div>
            
            <h2>Upcoming Catalysts Table</h2>
            <table border="1" class="dataframe table">
  <thead>
    <tr style="text-align: right;">
      <th>completion_date</th>
      <th>ticker</th>
      <th>phase</th>
      <th>market_cap</th>
      <th>pct_change_30d</th>
      <th>condition</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>2025-12-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma</td>
    </tr>
    <tr>
      <td>2025-12-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <td>2025-12-15</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Rotavirus Infection of Children</td>
    </tr>
    <tr>
      <td>2025-12-16</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm</td>
    </tr>
    <tr>
      <td>2025-12-18</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Cough, Refractory Chronic Cough</td>
    </tr>
    <tr>
      <td>2025-12-20</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Pancreatic Diseases</td>
    </tr>
    <tr>
      <td>2025-12-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>AML, ALL, MDS</td>
    </tr>
    <tr>
      <td>2025-12-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Colorectal Cancer</td>
    </tr>
    <tr>
      <td>2025-12-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>PMMR, MSS, MSI-L</td>
    </tr>
    <tr>
      <td>2025-12-22</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>HIV-1-infection</td>
    </tr>
    <tr>
      <td>2025-12-22</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)</td>
    </tr>
    <tr>
      <td>2025-12-23</td>
      <td>(RHHBY, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm</td>
    </tr>
    <tr>
      <td>2025-12-25</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Diffuse Large B-Cell Lymphoma</td>
    </tr>
    <tr>
      <td>2025-12-26</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Neuroblastoma</td>
    </tr>
    <tr>
      <td>2025-12-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease</td>
    </tr>
    <tr>
      <td>2025-12-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma</td>
    </tr>
    <tr>
      <td>2025-12-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Melasma (Facial Melasma)</td>
    </tr>
    <tr>
      <td>2025-12-29</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer, HER2-positive</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Primary Immune Thrombocytopenia</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Intrahepatic Cholangiocarcinoma</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hepatocellular Carcinoma</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Atopic Dermatitis</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Oligometastatic Prostate Cancer</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Endometrial Cancer, Atypical Endometrial Hyperplasia</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Colorectal Cancer</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Myeloma, Newly Diagnosed, High Risk</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Idiopathic Parkinson Disease</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Biliary Tract Cancer</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Solid Tumor, Adult</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Depression</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Soft Tissue Sarcoma</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Tumor Immunity, Immunosuppression, Radiofrequency Ablation</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Non-small Cell Lung Cancer</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Iron Deficiency Anemia of Pregnancy</td>
    </tr>
    <tr>
      <td>2025-12-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Vulvar Cancer, Vulvar Squamous Cell Carcinoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Erectile Dysfunction</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Malignant Female Reproductive System Neoplasm</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Gland, Salivary Gland Cancers</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(RHHBY, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer, Cholangiocarcinoma, Colorectal Cancer</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Esophagus Cancer</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(VYGR, 88)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Urothelial Carcinoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Mesenchymal Chondrosarcoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Asthma, Wheezing</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Anemia</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(RHHBY, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Non-small Cell Lung Cancer (NSCLC)</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Atrial Fibrillation</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer, Heart Failure</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Toripalimab, Radiation</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Tennis Elbow, Lateral Epicondylitis \(Tennis Elbow\), Lateral Elbow Tendinopathy</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Atrial Fibrillation, Atrial Flutter</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hepatocellular Carcinoma Non-resectable, HCC</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Anemia</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>T-cell Lymphoblastic Lymphoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Focal Hand Dystonia</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(PFE, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Melanoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>MCRC</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Congenital Adrenal Hyperplasia</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Healthy Adults</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Hepatocellular Carcinoma (HCC)</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>ST Segment Elevation Myocardial Infarction, Heart Failure</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Methanol Poisoning</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Long COVID, Long COVID-19, Hypersomnia</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Ischemic Stroke, Acute</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Cardiac Amyloidosis</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Cervical Cancer, Condylomata Acuminata</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Progression</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Esophageal Cancer, Nimotuzumab, Chemoradiotherapy</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Cancer, Anorexia, Weight Loss</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>DLBCL</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Primary Immune Thrombocytopenia (ITP)</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Alzheimer Disease</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Cancer Disease</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Ocular Graft-versus-host Disease</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>PTSD</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease</td>
    </tr>
    <tr>
      <td>2025-12-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Tuberous Sclerosis Complex, Epilepsy</td>
    </tr>
    <tr>
      <td>2026-01-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Sclerosis</td>
    </tr>
    <tr>
      <td>2026-01-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Inflammatory Disease, Aging Problems, Obese</td>
    </tr>
    <tr>
      <td>2026-01-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Pelvic Pain Syndrome</td>
    </tr>
    <tr>
      <td>2026-01-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Stroke Rehabilitation, Gait Disorders, Neurologic, tDCS</td>
    </tr>
    <tr>
      <td>2026-01-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Leptomeningeal Metastasis</td>
    </tr>
    <tr>
      <td>2026-01-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Myeloid Leukemia (AML)</td>
    </tr>
    <tr>
      <td>2026-01-05</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Mild or Moderate Asthma With Allergic Sensitization</td>
    </tr>
    <tr>
      <td>2026-01-07</td>
      <td>(AZN, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Cancer</td>
    </tr>
    <tr>
      <td>2026-01-09</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Fibrous Dysplasia</td>
    </tr>
    <tr>
      <td>2026-01-10</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Malaria, Malaria,Falciparum, Parasitic Disease</td>
    </tr>
    <tr>
      <td>2026-01-12</td>
      <td>(MRK, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Hodgkin Lymphoma</td>
    </tr>
    <tr>
      <td>2026-01-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Myeloma, Smoldering Multiple Myeloma</td>
    </tr>
    <tr>
      <td>2026-01-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Sepsis</td>
    </tr>
    <tr>
      <td>2026-01-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7</td>
    </tr>
    <tr>
      <td>2026-01-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Classical Hodgkin Lymphoma</td>
    </tr>
    <tr>
      <td>2026-01-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer</td>
    </tr>
    <tr>
      <td>2026-01-21</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma</td>
    </tr>
    <tr>
      <td>2026-01-27</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Disease or Disorder</td>
    </tr>
    <tr>
      <td>2026-01-27</td>
      <td>(CARA, 80)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced or Metastatic Solid Tumors</td>
    </tr>
    <tr>
      <td>2026-01-27</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Overweight, Obesity</td>
    </tr>
    <tr>
      <td>2026-01-28</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Hepatocellular Carcinoma</td>
    </tr>
    <tr>
      <td>2026-01-29</td>
      <td>(AZN, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Asthma</td>
    </tr>
    <tr>
      <td>2026-01-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Myelosuppression</td>
    </tr>
    <tr>
      <td>2026-01-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Myeloma</td>
    </tr>
    <tr>
      <td>2026-01-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System</td>
    </tr>
    <tr>
      <td>2026-01-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Myeloma</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Stroke, Acute Stroke, Ischemic Stroke</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Triple-Negative Breast Cancer (TNBC), Brain Metastases</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Pharmacokinetics of Celecoxib in Children</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Sickle Cell Anemia, Beta Thalassemia</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Pancreatic Cancer, Metastatic Pancreatic Cancer</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Relapsed/Refractory Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <td>2026-01-31</td>
      <td>(PHAT, 91)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hypothalamic Obesity</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Rectal Cancer</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Salivary Gland Cancer, HER2 Gene Mutation</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Recurrent or Metastatic Nasopharyngeal Carcinoma</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Immune-related Colitis, Colitis</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Pregnancy Related, Pre-Eclampsia</td>
    </tr>
    <tr>
      <td>2026-02-01</td>
      <td>(BEAM, 82)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Solid Tumor</td>
    </tr>
    <tr>
      <td>2026-02-10</td>
      <td>(AMGN, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Thyroid Eye Disease</td>
    </tr>
    <tr>
      <td>2026-02-11</td>
      <td>(MRK, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Carcinoma, Renal Cell</td>
    </tr>
    <tr>
      <td>2026-02-13</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Overweight or Obese</td>
    </tr>
    <tr>
      <td>2026-02-22</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Branch Atheromatous Disease</td>
    </tr>
    <tr>
      <td>2026-02-24</td>
      <td>(AZN, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Heart Failure</td>
    </tr>
    <tr>
      <td>2026-02-24</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Solid Tumors, Metastatic Solid Tumors</td>
    </tr>
    <tr>
      <td>2026-02-25</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <td>2026-02-28</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Carcinoma, Hepatocellular</td>
    </tr>
    <tr>
      <td>2026-02-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma</td>
    </tr>
    <tr>
      <td>2026-02-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Colon Cancer</td>
    </tr>
    <tr>
      <td>2026-02-28</td>
      <td>(NVS, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <td>2026-02-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Amyloidosis; Systemic</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>CMV</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Posttraumatic Headache</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Pulpotomy of Young Permanent Molars</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Gastric or Esophagogastric Junction Adenocarcinoma</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI)</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis</td>
    </tr>
    <tr>
      <td>2026-03-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Inflammatory Response After Surgery, Postoperative Recovery</td>
    </tr>
    <tr>
      <td>2026-03-02</td>
      <td>(NVS, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Warm Autoimmune Hemolytic Anemia (wAIHA)</td>
    </tr>
    <tr>
      <td>2026-03-03</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Modified Radical Mastectomy, Breast Cancer</td>
    </tr>
    <tr>
      <td>2026-03-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer</td>
    </tr>
    <tr>
      <td>2026-03-15</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)</td>
    </tr>
    <tr>
      <td>2026-03-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer</td>
    </tr>
    <tr>
      <td>2026-03-15</td>
      <td>(OLMA, 81)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Obstructive Hypertrophic Cardiomyopathy</td>
    </tr>
    <tr>
      <td>2026-03-15</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC V8</td>
    </tr>
    <tr>
      <td>2026-03-18</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Ischemic Stroke, Large Vessel Occlusion, Endovascular Treatment</td>
    </tr>
    <tr>
      <td>2026-03-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Non-hodgkin Lymphoma,B Cell</td>
    </tr>
    <tr>
      <td>2026-03-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma</td>
    </tr>
    <tr>
      <td>2026-03-26</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer</td>
    </tr>
    <tr>
      <td>2026-03-26</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms</td>
    </tr>
    <tr>
      <td>2026-03-27</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Hidradenitis Suppurativa</td>
    </tr>
    <tr>
      <td>2026-03-29</td>
      <td>(BMY, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Systemic Lupus Erythematosus</td>
    </tr>
    <tr>
      <td>2026-03-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Solid Tumors, Advanced Cancer, Renal Cancer</td>
    </tr>
    <tr>
      <td>2026-03-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Coronary Syndrome</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Neurogenic Bladder, Post-operative Urinary Tract Infections</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Allogeneic Stem Cell Transplantation</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(MIST, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Paroxysmal Supraventricular Tachycardia</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Rift Valley Fever</td>
    </tr>
    <tr>
      <td>2026-03-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Kidney Diseases</td>
    </tr>
    <tr>
      <td>2026-04-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Renal Cell Carcinoma</td>
    </tr>
    <tr>
      <td>2026-04-01</td>
      <td>(ALNY, 87)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases</td>
    </tr>
    <tr>
      <td>2026-04-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hiv</td>
    </tr>
    <tr>
      <td>2026-04-01</td>
      <td>(VKTX, 88)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Thyroid Eye Disease</td>
    </tr>
    <tr>
      <td>2026-04-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer</td>
    </tr>
    <tr>
      <td>2026-04-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19</td>
    </tr>
    <tr>
      <td>2026-04-02</td>
      <td>(NVS, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Spontaneous Urticaria</td>
    </tr>
    <tr>
      <td>2026-04-03</td>
      <td>(RHHBY, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Moderate to Severe Ulcerative Colitis</td>
    </tr>
    <tr>
      <td>2026-04-05</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Unresectable Hepatocellular Carcinoma</td>
    </tr>
    <tr>
      <td>2026-04-13</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Sub-arachnoid Haemorrhage</td>
    </tr>
    <tr>
      <td>2026-04-14</td>
      <td>(MRNA, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Norovirus Acute Gastroenteritis</td>
    </tr>
    <tr>
      <td>2026-04-18</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Burns Surgery</td>
    </tr>
    <tr>
      <td>2026-04-19</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma</td>
    </tr>
    <tr>
      <td>2026-04-20</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Rectal Squamous Cell Carcinoma</td>
    </tr>
    <tr>
      <td>2026-04-22</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Esophageal Cancer, Dysphagia, Esophageal, Epigallocatechin Gallate</td>
    </tr>
    <tr>
      <td>2026-04-22</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hematologic Malignancies</td>
    </tr>
    <tr>
      <td>2026-04-22</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Solid Malignancies</td>
    </tr>
    <tr>
      <td>2026-04-24</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Cleft Lip and Palate</td>
    </tr>
    <tr>
      <td>2026-04-26</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Myeloma</td>
    </tr>
    <tr>
      <td>2026-04-26</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Chemotherapy-induced Peripheral Neuropathy</td>
    </tr>
    <tr>
      <td>2026-04-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Carcinoma, Non-Small-Cell Lung</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Physical Activity</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(NVS, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Relapsing Multiple Sclerosis</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Asthma With Allergic Rhinitis</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Triple-negative Breast Cancer, Cadonilimab</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Primary Immunodeficiency Disease</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(VRTX, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Cystic Fibrosis</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(MRK, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant</td>
    </tr>
    <tr>
      <td>2026-04-30</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Non Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <td>2026-05-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Stem Cells, Type 1 Diabetes</td>
    </tr>
    <tr>
      <td>2026-05-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Locally Advanced Thymoma</td>
    </tr>
    <tr>
      <td>2026-05-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma</td>
    </tr>
    <tr>
      <td>2026-05-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown</td>
    </tr>
    <tr>
      <td>2026-05-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Breast Cancer Female, Hormone Receptor Positive Tumor</td>
    </tr>
    <tr>
      <td>2026-05-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence</td>
    </tr>
    <tr>
      <td>2026-05-03</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Ovarian Cancer, Ovarian Carcinoma</td>
    </tr>
    <tr>
      <td>2026-05-06</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>PNH - Paroxysmal Nocturnal Hemoglobinuria</td>
    </tr>
    <tr>
      <td>2026-05-11</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms</td>
    </tr>
    <tr>
      <td>2026-05-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Colorectal Cancer</td>
    </tr>
    <tr>
      <td>2026-05-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Myeloid Leukemia, Adult</td>
    </tr>
    <tr>
      <td>2026-05-15</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Diabetic Kidney Disease (DKD)</td>
    </tr>
    <tr>
      <td>2026-05-19</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Posttraumatic Headache, Mild Traumatic Brain Injury</td>
    </tr>
    <tr>
      <td>2026-05-25</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Psoriatic Arthritis</td>
    </tr>
    <tr>
      <td>2026-05-26</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</td>
    </tr>
    <tr>
      <td>2026-05-26</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Bronchial Asthma</td>
    </tr>
    <tr>
      <td>2026-05-28</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma</td>
    </tr>
    <tr>
      <td>2026-05-29</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Major Depressive Disorder</td>
    </tr>
    <tr>
      <td>2026-05-29</td>
      <td>(AZN, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Hepatocellular Carcinoma</td>
    </tr>
    <tr>
      <td>2026-05-29</td>
      <td>(DGXA, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis</td>
    </tr>
    <tr>
      <td>2026-05-30</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Follicular Lymphoma, Marginal Zone Lymphoma</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(BMY, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Myelofibrosis</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Antiphospholipid Syndrome (APS)</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Liver Cirrhosis</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Waldenstrm's Macroglobulinemia</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(VRTX, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Proteinuric Kidney Disease</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Sickle Cell Disease</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Dyslipidemias</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Lymphocytic Leukemia</td>
    </tr>
    <tr>
      <td>2026-05-31</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Aneurysm, Behcet Syndrome, Vascular Type</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Glioma, IDH Mutation, Astrocytoma</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Metastatic Pancreatic Ductal Adenocarcinoma</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Keratoconus, Ectasia Corneal</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Fungal Infection, Haematological Malignancy, Blood Cancer</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Glanzmann Thrombasthenia</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Hepatocellular Carcinoma, HCC</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(BIIB, 100)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Lupus Nephritis</td>
    </tr>
    <tr>
      <td>2026-06-01</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Primary Sclerosing Cholangitis</td>
    </tr>
    <tr>
      <td>2026-06-02</td>
      <td>(None, 0)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Diabetes Mellitus, Type 2</td>
    </tr>
    <tr>
      <td>2026-06-02</td>
      <td>(AZN, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Esophageal Squamous Cell Carcinoma</td>
    </tr>
    <tr>
      <td>2026-06-04</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Multiple Sclerosis</td>
    </tr>
    <tr>
      <td>2026-06-04</td>
      <td>(BIIB, 100)</td>
      <td>Phase 3</td>
      <td></td>
      <td>0.0</td>
      <td>Choroideremia, X-Linked Retinitis Pigmentosa</td>
    </tr>
    <tr>
      <td>2026-06-11</td>
      <td>(None, 0)</td>
      <td>Phase 2</td>
      <td></td>
      <td>0.0</td>
      <td>Thrombotic Thrombocytopenic Purpura (TTP)</td>
    </tr>
  </tbody>
</table>
        </div>
    </body>
    </html>
    